Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.82 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.73 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.70 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.70 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | RECQL | P46063 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335183 | 1.00 | HSD17B2 (0.82) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| SCHEMBL6239788 | 1.00 | HSD17B2 (0.82) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| SCHEMBL6238427 | 0.92 | HSD17B2 (0.78) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| Jaceosidine SCHEMBL3960077 | 0.90 | HSD17B2 (1.00) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| Jaceosidine SCHEMBL29926544 | 0.90 | HSD17B2 (1.00) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| SCHEMBL30037622 | 0.90 | HSD17B2 (0.77) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| Cirsileneol SCHEMBL2045672 | 0.88 | HSD17B2 (0.86) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| Cirsileneol SCHEMBL29435128 | 0.88 | HSD17B2 (0.86) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| SCHEMBL10001101 | 0.87 | HSD17B2 (0.70) | HSD17B2TAS2R31KMT2AMEN1POLB | |
| SCHEMBL10001093 | 0.87 | HSD17B2 (0.73) | HSD17B2TAS2R31KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250046528-A1 | ELECTROLYTIC CAPACITOR AND LIQUID COMPONENT FOR ELECTROLYTIC CAPACITOR | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | disclosed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230082651-A1 | STABLE AQUEOUS COMPOSITIONS OF PLANTS EXTRACTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| US-20230079480-A1 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | Nulixir Inc. | 2023-03-16 | — | — | US | disclosed |
| EP-4142728-A1 | 6'-METHOXYCINCHONAN-9-OLS FOR THE TREATMENT OF CORONAVIRAL INFECTIONS | Immunologik GmbH (DE) | 2023-03-08 | — | — | EP | disclosed |
| CN-115515587-A | 6' -methoxycinchonin-9-ols for the treatment of coronavirus infections | 免疫学有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | HSD17B2 1898/4885TAS2R31 3770/4885KMT2A 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.